investment Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their future products. You founded Milestone Pharmaceuticals in 2005, having founded Galileo Genomics and Allostera Pharma.What were the main objectives in founding Milestone? I was one of four founders of Milestone. The idea…
Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…
R&D-based Pharmaceutical Association Committe You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say that it is easier or harder to tackle today or a decade ago? In my view, the Chinese market is…
Biocon If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage in an infrastructure deficient Bangalore. Both India and Biocon have come a long way since then. How different is the…
Glenmark Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it across 140 countries. What stage of the process are you in? When will we see India’s first novel drug in…
See our Cookie Privacy Policy Here
